Tags : EVOLVE-MS-2

Biogen and Alkermes Report Results of Diroximel Fumarate in P-III

Tuba Khan July 31, 2019

Shots: The P-III EVOLVE-MS-2 study assessing the GI tolerability of Diroximel Fumarate (462mg, bid) vs Tecfidera (dimethyl fumarate, 240 mg, bid) in 506 patients with RRMS The P-III EVOLVE-MS-2 study […]readmore

Tags : EVOLVE-MS-2

Biogen and Alkermes Report Results of Diroximel Fumarate in P-III

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : EVOLVE-MS-2

﻿Biogen and Alkermes Report Results of Diroximel Fumarate in P-III

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Biogen and Alkermes Report Results of Diroximel Fumarate in P-III